Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
AmerisourceBergen Corp. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Income Statement
- Analysis of Liquidity Ratios
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AmerisourceBergen Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
The analysis of the financial ratios over the reported periods reveals several notable trends and fluctuations.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio shows a consistent upward trajectory from the fourth quarter of 2016 through the second quarter of 2023. Starting around 85 in late 2016, the ratio increased steadily, peaking above 132 in early 2021. Afterward, there was a noticeable dip, dropping to around 95 by the third quarter of 2021. Following this decline, the ratio resumed its upward trend, recovering and rising above 118 by mid-2023. This pattern suggests increasing efficiency in utilizing fixed assets, with some volatility observed between 2020 and 2021.
- Total Asset Turnover
- Total asset turnover ratios exhibited a modest downward trend from late 2016 until reaching a low point in the third quarter of 2021. Initially situated above 4.3, the ratio declined gradually to approximately 3.65 by the third quarter of 2021. Subsequently, the ratio showed signs of recovery, climbing back above 4.2 by mid-2023. The trend indicates a period of reduced efficiency in generating revenue from total assets, followed by a partial improvement more recently.
- Equity Turnover
- The equity turnover ratio displays high volatility and inconsistency across the periods. The ratio begins with moderate values in 2016-2018, generally ranging between 49 and 74, with a peak near 74 in late 2016. Following this, values fluctuate with no clear pattern until 2020, where reported data is missing. Notably, a dramatic and anomalously high spike occurs between 2021 and 2022, where ratios surpass several hundreds and even exceed 5,000 at one point, which appear to be outliers or potential data irregularities. Post-spike, the ratios decrease sharply but remain volatile, with inconsistent values in 2023. This extreme variation complicates the interpretation but suggests extraordinary fluctuations in equity utilization or possibly data errors during that timeframe.
Overall, the net fixed asset turnover shows a positive long-term trend with some temporary declines, highlighting improving asset use efficiency. The total asset turnover trend indicates some efficiency challenges with a recent rebound. The equity turnover data is erratic, requiring further verification due to unusual spikes and missing data, which may suggest extraordinary events or inconsistencies in the measurement or reporting periods.
Net Fixed Asset Turnover
Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||||||||
Revenue | |||||||||||||||||||||||||||||||||||
Property and equipment, net | |||||||||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||||||||
Net fixed asset turnover1 | |||||||||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Q3 2023 Calculation
Net fixed asset turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenue Trend
-
Revenue exhibited a generally increasing trend over the observed periods, starting from approximately $38.2 billion at the end of 2016 and reaching around $66.9 billion by mid-2023. There were minor fluctuations within quarters, such as a decline from $45.4 billion in Q4 2018 to $43.3 billion in Q1 2019, and variability around early 2020 likely related to external factors. However, strong recovery and consistent growth are observable particularly from late 2020 onward, with a notable acceleration in revenue from approximately $49.2 billion in Q4 2020 to nearly $67 billion by Q2 2023.
- Property and Equipment, Net
-
The net value of Property and Equipment showed some variation but generally remained within a range of about $1.4 billion to $2.1 billion across the period. There was a noticeable decline around late 2019 and early 2020, dropping from about $1.8 billion towards $1.4 billion, followed by a recovery and stabilization just above $2.1 billion from late 2020 through mid-2023. This suggests capital asset disposals or revaluations in 2019-2020, with subsequent reinvestment or asset additions maintaining the asset base.
- Net Fixed Asset Turnover Ratio
-
This ratio, which measures revenue generated per unit of fixed asset, was not reported initially, but from mid-2017 onwards shows a generally high and increasing trend. The ratio was around 85 in Q2 2017, rising steadily to peak above 132 in mid and late 2021. A dip occurred towards late 2021 and early 2022, dropping into the mid-90s to low 100s, before rising again to exceed 118 by mid-2023. The pattern suggests improved efficiency in utilizing fixed assets to generate revenue over time, with periods of moderate decline possibly reflecting asset base adjustments or operational changes. The higher turnover ratios in recent quarters indicate enhanced asset productivity relative to earlier periods.
Total Asset Turnover
Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||||||||
Revenue | |||||||||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||||||||
Total asset turnover1 | |||||||||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Q3 2023 Calculation
Total asset turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenue Trends
- The revenue figures exhibit an overall increasing trend from December 31, 2016, through June 30, 2023. Starting at approximately $38.2 billion in late 2016, the revenue experienced fluctuations with periods of consolidation and growth. Noticeable growth periods occurred in late 2017, late 2018, and most significantly from late 2020 through mid-2023. The revenue peaked around $66.9 billion in June 2023, indicating substantial expansion over the analyzed timeframe.
- Total Assets Evolution
- Total assets have shown a steady upward trajectory during the period from late 2016 to mid-2023. Beginning at approximately $33.9 billion, total assets rose gradually to about $61.2 billion by June 2023. The increases were consistent with periodic increments in investment or asset acquisition, contributing to a sizeable growth in the asset base. There were minor fluctuations and plateaus, but the general movement was positive, signifying asset base expansion aligned with operational scaling.
- Total Asset Turnover Dynamics
- The total asset turnover ratio, provided intermittently from June 30, 2017, onward, mostly ranged between 3.65 and 4.61. Initially, the ratio hovered above 4.0 through late 2019, reflecting a relatively efficient use of assets in generating revenue. Subsequently, a decline was observed in 2021 to values around 3.65, indicating a temporary reduction in asset utilization efficiency. However, starting from late 2021, there was a recovery trend, with turnover ratios climbing back above 4.0 and stabilizing around those levels through mid-2023. This suggests an improvement in operational efficiency in asset use in the more recent periods.
- Integrated Insights
- The steady increase in both revenue and total assets suggests expansion in business scale and capacity. The initial decline in total asset turnover during 2021 could relate to rapid asset growth or revenue disruptions, possibly due to market conditions, which temporarily impacted asset efficiency. The recovery in turnover ratio alongside the continued revenue rise indicates a favorable adjustment period leading to regained operational efficiency. Overall, the data points to robust growth with evolving asset management effectiveness through the analyzed timeframe.
Equity Turnover
Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||||||||
Revenue | |||||||||||||||||||||||||||||||||||
Total AmerisourceBergen Corporation stockholders’ equity (deficit) | |||||||||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||||||||
Equity turnover1 | |||||||||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | |||||||||||||||||||||||||||||||||||
Abbott Laboratories | |||||||||||||||||||||||||||||||||||
CVS Health Corp. | |||||||||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Q3 2023 Calculation
Equity turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Total AmerisourceBergen Corporation stockholders’ equity (deficit)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The revenue exhibits an overall upward trend across the analyzed periods, increasing from approximately 38.2 billion US dollars at the end of 2016 to nearly 67.0 billion US dollars by the second quarter of 2023. While the growth is generally consistent, certain quarters reveal fluctuations, such as a slight dip in the first quarter of 2019 followed by recovery in subsequent periods. A notable acceleration in revenue growth can be observed from late 2020 through 2021, with revenue crossing the 50 billion US dollar mark and reaching new highs around 58.9 billion US dollars by the fourth quarter of 2021. The upward trajectory continues thereafter albeit with some quarterly volatility.
Regarding total stockholders’ equity, there is a marked variability throughout the periods. Initial values remain positive, beginning at approximately 2.1 billion US dollars at the end of 2016 and reaching peaks around 3.8 billion US dollars in the first quarter of 2020. However, from mid-2020 onward, equity experiences significant declines culminating in negative values in several quarters, notably reaching a low close to -1.0 billion US dollars in the third quarter of 2020. This negative trend persists for multiple periods through mid-2022, before equity returns to a positive position, reaching around 686 million US dollars by the second quarter of 2023. This swing from positive to negative and back suggests episodes of financial distress or substantial balance sheet reconfigurations over this timeframe.
The reported equity turnover ratio data is sparse and irregular, with values missing for most earlier quarters and only appearing significantly from late 2017 onwards. The available values indicate high variability and some extreme spikes, with ratios as high as 5382.26 and 1053.62 observed in mid-2021 and end-2021 respectively. Such spikes imply substantial revenue generation relative to equity at certain points, coinciding with periods when equity was approaching zero or negative territory. This behavior underscores the impact of the aforementioned equity fluctuations on operational efficiency metrics and suggests caution when interpreting this ratio due to its sensitivity to equity base size.
In summary, the company demonstrates strong and growing revenue performance over the period but faces considerable volatility and challenges in maintaining positive stockholders’ equity. The fluctuations in equity, including periods of deficit, influence the interpretation of efficiency metrics such as equity turnover, which show inconsistent and extreme values. Continuous monitoring of equity trends is advised to assess financial stability alongside revenue growth.